Fractyl Health (GUTS) Receivables - Net (2023 - 2024)

Fractyl Health's (GUTS) quarterly Receivables - Net came in at $22000.0 in Q2 2024, up 46.67% on a QoQ basis from $15000.0 in Q1 2024.

Fractyl Health (GUTS) Receivables - Net (2023 - 2024) Analysis & Trends

Fractyl Health (GUTS) has 2 years of Receivables - Net data on file, last reported at $22000.0 in Q2 2024.

Quarterly Receivables - Net changed N/A year-over-year to $22000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $22000.0 (changed N/A YoY) and the FY2023 annual result came in at $22000.0, changed N/A from the prior year.
Receivables - Net advanced to $22000.0 in Q2 2024, from $15000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $22000.0 in Q4 2023 to a low of $15000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.87 Bn	78.87 Bn	3.93 Bn
3	Argenx Se	65.40 Bn	60.22 Bn	1.37 Bn
4	Moderna	59.36 Bn	54.22 Bn	52.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.91 Bn	28.60 Bn	992.69 Mn
7	BioNTech SE	28.17 Bn	9.78 Bn	668.28 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-
10	Fractyl Health	125.68 Mn	125.68 Mn	-

Download Data